NUFORMIX PLC Logo

NUFORMIX PLC

Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.

NFX | IL

Overview

Corporate Details

ISIN(s):
GB00BYW79Y38
LEI:
2138003XG3H3I2J3BJ24
Country:
United Kingdom
Address:
6TH FLOOR, EC3V 0HR LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nuformix PLC is a pharmaceutical development company that specializes in drug repurposing to address unmet medical needs, primarily in fibrosis and oncology. The company leverages its proprietary cocrystal technology to unlock and enhance the therapeutic potential of known, approved drugs. This approach aims to improve the physical properties of existing medicines, thereby creating a pipeline of novel treatments for its target therapeutic areas.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-10 08:00
Board/Management Information
Change of Auditor
English 9.3 KB
2025-08-11 08:00
Legal Proceedings Report
US FDA ODD Application Submitted for NXP002
English 13.5 KB
2025-05-29 08:00
Regulatory News Service
Confirmation of European ODD for NXP002
English 13.6 KB
2025-05-28 11:28
Prospectus
Nuformix plc - Single prospectus
English 866.5 KB
2025-05-23 14:19
Prospectus
Prospectus
English 866.5 KB
2025-05-23 14:08
Report Publication Announcement
Publication of a Prospectus
English 13.3 KB
2025-02-28 13:30
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 9.3 KB
2025-02-14 15:18
Report Publication Announcement
Posting of Annual Report and Notice of AGM
English 8.4 KB
2025-01-30 08:00
Share Issue/Capital Change
£168,750 Placing
English 13.1 KB
2025-01-29 08:00
Annual / Quarterly Financial Statement
Annual Results for period ended 30 September 2024
English 414.7 KB
2025-01-28 08:00
Regulatory News Service
NXP002 ODD Application Submitted
English 11.4 KB
2025-01-13 08:00
Regulatory News Service
NXP002 Orphan Drug Designation Draft Application
English 9.6 KB
2024-11-29 18:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 9.1 KB
2024-11-05 15:25
Director's Dealing
Director/PDMR Dealings
English 39.9 KB
2024-11-04 11:17
Declaration of Voting Results & Voting Rights Announcements
Result of General Meeting
English 21.2 KB

Automate Your Workflow. Get a real-time feed of all NUFORMIX PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NUFORMIX PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NUFORMIX PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.